Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spyre TherapeuticsSYRE +6.49%26 PB Ratio is 15.32 as of Jul. 18, 2026, which is 756% above its 10-year median of 1.79. GuruFocus rates SYRE with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 1,227 Biotechnology companies, Spyre Therapeutics ranks worse than 90.55% on this metric.
Spyre Therapeutics Inc stock PB Ratio (=14.41) is close to 10-year high of 14.41.
The historical rank and industry rank for Spyre Therapeutics's PB Ratio or its related term are showing as below:
SYRE'
s PB Ratio Range Over the Past 10 Years
Min: 0.25 Med: 1.79 Max: 15.48
Current: 15.35
During the past 13 years, Spyre Therapeutics's highest PB Ratio was 15.48. The lowest was 0.25. And the median was 1.79.
SYRE's PB Ratio is ranked worse than 90.55% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs SYRE: 15.35
During the past 12 months, Spyre Therapeutics's average Book Value Per Share Growth Rate was 20.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -28.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Spyre Therapeutics was -1.10% per year. The lowest was -47.90% per year. And the median was -25.95% per year.
Back to Basics: PB Ratio
Spyre Therapeutics (NAS:SYRE) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Spyre Therapeutics PB Ratio Related Terms
Spyre Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Spyre Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spyre Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Spyre Therapeutics (SYRE) has a PB Ratio of 15.32 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Spyre Therapeutics and its competitors. This is 756% above median its historical median of 1.79. Over the past decade, Spyre Therapeutics' PB Ratio has ranged from 0.25 to 15.48. According to the industry distribution chart, Spyre Therapeutics ranks #1111 out of 1227 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Spyre Therapeutics' PB Ratio too high?
Spyre Therapeutics' current PB Ratio of 15.32 is 756% above median its 10-year median of 1.79. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 15.48. The Biotechnology industry median PB Ratio is 2.82. Spyre Therapeutics' value of 15.32 is 443.3% above this industry median. Based on the distribution chart, Spyre Therapeutics ranks #1111 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' PB Ratio compare to MIRM and RYTM?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #1111 out of 1227 companies for PB Ratio. This places Spyre Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.82. Spyre Therapeutics' value of 15.32 is 443.3% above this benchmark. Historically, Spyre Therapeutics' own PB Ratio has ranged from 0.25 to 15.48 over the past decade. While the company's 10-year median is 1.79 vs. the industry median of 2.82, Spyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spyre Therapeutics's current PB Ratio of 15.32 is 443.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current PB Ratio is 15.32, which is 756% above median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (SYRE) has a current PB Ratio of 15.32. The current PB Ratio is 15.32, which is 756% above median its 10-year median of 1.79 and 443.3% above the Biotechnology industry median of 2.82. Spyre Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Spyre Therapeutics (SYRE), the current PB Ratio is 15.32 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score
Get the complete analysis for SYRE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRE has been successfully added to your 
